Table 4.

Demographics, CUP classification and genomic results of 14 patients treated with targeted therapy.

Age	Sex	CUP subtype	CUP subtype detail	Molecular target identified	Molecular target detail	Targeted therapy
60	M	Favourable	Renal-like	No	—	Pazopanib
59	M	Favourable	Lung-like	Yes	EGFR exon 18 mutation	Erlotinib
63	M	Favourable	Colon-like	No	—	Regorafenib
56	F	Favourable	Breast-like	Yes	ERBB2 amplification	Trastuzumab and pertuzumab
73	F	Favourable	Breast-like	Yes	ERBB2 amplification	Trastuzumab and pertuzumab
60	F	Unfavourable	—	Yes	MYC amplification	BET inhibitor
70	M	Unfavourable	—	Yes	BRCA2 mutation	Talazoparib
64	F	Unfavourable	—	No	—	Pazopanib
69	F	Favourable	Renal-like	No	—	Pazopanib
64	M	Unfavourable	—	Yes	CDK3 mutation	Ribociclib and trametinib
71	M	Favourable	Renal-like	No	—	Pazopanib
24	F	Unfavourable	—	Yes	PIK3CA and PTEN alterations	Ipatasertib
48	M	Unfavourable	—	Yes	BRAF mutation	Vemurafenib
39	F	Unfavourable	—	Yes	ERBB2 amplification	Trastuzumab, Ado-trastuzumab emtansine

BET Bromodomain and Extra-Terminal motif.